Variations of movement disorders in anti-N-methyl-D-aspartate receptor encephalitis A nationwide study in Taiwan

Medicine (United States)

Volumn 95, Issue 37, 2016, Pages

  Duan, Bi Chun ^a   Weng, Wen Chin ^a   Lin, Kuang Lin ^b   Wong, Lee Chin ^a   Li, Sung Tse ^c   Hsu, Mei Hsin ^b   Lin, Jainn Jim ^b   Fan, Pi Chaun ^a   Lin, Ming I ^d   Chiu, Nan Chang ^c   Lin, Yu Ching ^e   Wang, Huei Shyong ^b   Hung, Kun Long ^f   Lee, Wang Tso ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Anti N methyl D aspartate receptor; Autoimmune; Encephalitis; Movement disorders; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; RITUXIMAB; STEROID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ARTICLE; BRADYKINESIA; CATATONIA; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CHILD; CHOREOATHETOSIS; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE DURATION; DISEASE SEVERITY; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; INCIDENCE; INFANT; MALE; MOTOR DYSFUNCTION; OROFACIAL DYSKINESIA; OUTCOME ASSESSMENT; OVARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; TAIWAN; TREMOR; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; COMPLICATION; MOVEMENT DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; CHILD; FEMALE; HUMANS; MALE; MOVEMENT DISORDERS; RETROSPECTIVE STUDIES; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84991696523     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004365     Document Type: Article

References (37)

1. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12: 157-65.
2. Wandinger KP, Saschenbrecker S, Stoecker W, et al. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol 2011;231:86-91.
3. Hsu MH, Huang CC, Hung PL, et al. Paraneoplastic neurological disorders in children with benign ovarian tumors. Brain Develop 2014;36:248-53.
4. Baizabal-Carvallo JF, Stocco A, Muscal E, et al. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 2013;28:543-7.
5. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63-74.
6. Thomas A, Rauschkolb P, Gresa-Arribas N, et al. Anti-N-methyl-D-aspartate receptor encephalitis: a patient with refractory illness after 25 months of intensive immunotherapy. JAMA Neurol 2013;70: 1566-8.
7. Barry H, Byrne S, Barrett E, et al. Anti-N-methyl-d-aspartate receptor encephalitis: review of clinical presentation, diagnosis and treatment. BJPsych Bull 2015;39:19-23.
8. Goldberg EM, Titulaer M, de Blank PM, et al. Anti-N-methyl-D-aspartate receptor-mediated encephalitis in infants and toddlers: case report and review of the literature. Pediatr Neurol 2014;50: 181-4.
9. Armangue T, Titulaer MJ, Malaga I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013;162:850-6. e852.
10. Raha S, Gadgil P, Sankhla C, et al. Nonparaneoplastic anti-N-methyl-d-aspartate receptor encephalitis: a case series of four children. Pediatr Neurol 2012;46:246-9.
11. Hacohen Y, Dlamini N, Hedderly T, et al. N-methyl-D-aspartate receptor antibody-associated movement disorder without encephalopa-thy. Develop Med Child Neurol 2014;56:190-3.
12. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11-8.
13. Mohammad SS, Fung VS, Grattan-Smith P, et al. Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies. Mov Disord 2014;29:1539-42.
14. Baizabal-Carvallo JF, Jankovic J. Movement disorders in autoimmune diseases. Mov Disord 2012;27:935-46.
15. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-8.
16. Poloni C, Korff CM, Ricotti V, et al. Severe childhood encephalopathy with dyskinesia and prolonged cognitive disturbances: evidence for anti-N-methyl-D-aspartate receptor encephalitis. Develop Med Child Neurol 2010;52:e78-82.
17. Kulkarni SK, Naidu PS. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today (Barcelona, Spain: 1998) 2003;39:19-49.
18. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-75.
19. Mink JW. The basal ganglia and involuntary movements: impaired inhibition of competing motor patterns. Arch Neurol 2003;60:1365-8.
20. Berardelli A. Symptomatic or secondary basal ganglia diseases and tardive dyskinesias. Curr Opin Neurol 1995;8:320-2.
21. Palacios JM, Camps M, Cortés R. Obeso JA, Horowski R, Marsden CD, et al. Mapping dopamine receptors in the human brain. Continuous Dopaminergic Stimulation in Parkinson's Disease. Vol 27. Vienna: Springer; 1988. 227-35.
22. Herrero MT, Barcia C, Navarro JM. Functional anatomy of thalamus and basal ganglia. Childs Nerv Syst 2002;18:386-404.
23. Sanger TD. Pathophysiology of pediatric movement disorders. J Child Neurol 2003;18(Suppl 1):S9-24.
24. Salvucci A, Devine IM, Hammond D, et al. Pediatric anti-NMDA (N-methyl D-aspartate) receptor encephalitis. Pediatr Neurol 2014;50: 507-10.
25. Hallett M. THe neurophysiology of dystonia. Arch Neurol 1998;55: 601-3.
26. Jucaite A, Forssberg H, Karlsson P, et al. Age-related reduction in dopamine D1 receptors in the human brain: from late childhood to adulthood, a positron emission tomography study. Neuroscience 2010;167:104-10.
27. Rinne JO, Lönnberg P, Marjamäki P. Age-dependent decline in human brain dopamine D1 and D2 receptors. Brain Res 1990;508:349-52.
28. Northoff G. Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J Neural Transm 2002;109: 1453-67.
29. Carroll BT. The universal field hypothesis of catatonia and neuroleptic malignant syndrome. CNS Spect 2000;5:26-33.
30. Binstadt BA, Caldas AMC, Turvey SE, et al. Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr 2003; 143:598-604.
31. Nosadini M, Mohammad SS, Ramanathan S, et al. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurotherap 2015;15:1391-419.
32. Wang H. Efficacies of treatments for anti-NMDA receptor encephalitis. Front Biosci (Landmark edition) 2016;21:651-63.
33. Sartori S, Nosadini M, Cesaroni E, et al. Paediatric anti-N-methyl-D-aspartate receptor encephalitis: the first Italian multicenter case series. Eur J Paediatr Neurol 2015;19:453-63.
34. Hung YC, Chang WC, Chen LM, et al. Non-genomic estrogen/estrogen receptor alpha promotes cellular malignancy of immature ovarian teratoma in vitro. J Cell Physiol 2014;229:752-61.
35. Lazar-Molnar E, Tebo AE. Autoimmune NMDA receptor encephalitis. Clin Chim Acta 2015;438:90-7.
36. Kurian M, Fluss J, Korff C. Anti-NMDA receptor encephalitis: the importance of early diagnosis and aggressive immunotherapy in tumor negative pediatric patients. Eur J Paediatr Neurol 2012;16:764-5.
37. Mann AP, Grebenciucova E, Lukas RV. Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management, and challenges. Therap Clin Risk Manag 2014;10:517-25.